SIMBRINZA® Suspension BID as an Adjunctive to Prostaglandin Analogue (PGA)
Status:
Completed
Trial end date:
2018-02-27
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the additive intraocular pressure (IOP) lowering
effect of brinzolamide 1%/brimonidine 0.2% (dosed twice per day (BID)) when added to a
prostaglandin analogue (PGA) in subjects with open-angle glaucoma or ocular hypertension.